Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.57 |
| ▸ | SCN1A | P35498 | 1/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432824 | 1.00 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2460187 | 0.85 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2460185 | 0.85 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2454333 | 0.84 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29791125 | 0.84 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2545942 | 0.84 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2456327 | 0.84 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2546729 | 0.84 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL2544714 | 0.84 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29791144 | 0.84 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338662-A1 | ALPHA-2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELISCHAFT (DE) | 2021-11-04 | — | — | US | claimed |
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2011-10-27 | — | — | US | claimed |
| US-20210338662-A1 | ALPHA-2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELISCHAFT (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2011-10-27 | — | — | US | disclosed |
| EP-2364303-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338662-A1 | ALPHA-2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA2A | ADRA2A 3/4885ADRA2B 4/4885ADRA2C 1/4885 |
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ADRA2C, ADRA2A, HTR2C | ADRA2A 2/4885ADRA2B 5/4885ADRA2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.